News

Cancer patients who receive high-tech proton therapy experience similar cure rates and fewer serious side effects compared with those who undergo traditional X-ray radiation therapy, according to a study led by Washington University School of Medicine in St. Louis and the Perelman…

One in four cancer patients experienced a delay to their diagnosis that could have been avoided, according to a new study by Cancer Research UK. It found that nearly 3,400 of 14,300 patients experienced a delay that could have been avoided. Half of…

A person’s risk of developing cancer is affected by genetic variations in regions of DNA that don’t code for proteins, previously dismissed as ‘junk DNA’, according to new research published in the British Journal of Cancer. This new study shows that inherited cancer risk…

A targeted cancer drug has been approved for use on the NHS in Scotland for patients with advanced, newly diagnosed ovarian cancer that’s responded to chemotherapy. Olaparib (Lynparza) tablets will be used to help prolong the effects of initial treatment, as a so-called…

The National Institute for Health and Care Excellence (NICE) has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. Trial results have shown that olaparib, which stops cancer cells repairing damage to their DNA, can…

A blood test can help identify rare mutations in advanced breast cancer, which may enable patients to access effective treatments more quickly in the future, Cancer Research UK scientists have found. As part of the plasmaMATCH clinical trial, funded by Stand Up To Cancer, a joint…

2019 was a year jam packed  with  brilliant progress and  new  challenges for cancer research. Here are some of the top stories of the year:  Re-writing the breast cancer rulebook, A cancer breath test enters trials, three new teams take on some of the biggest challenges in cancer research, tracking cancer evolution with…

Cancer Research UK and Vaccitech Oncology Limited (VOLT), announced Wednesday that a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer. The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is…

New headlines on cancer research: -A prostate cancer MRI trial is in progress -Treatment that delivers drugs straight to tumor given for the first time -WHO approves cheap copy of common breast cancer drug -Facebook bans ads promoting fake cancer "cures" -Post-menopausal women who are overweight…